AC01 / AnaCardio - LARVOL DELTA

The ghrelin receptor agonist AC01 improves cardiac function in non-human primates and in mice with heart failure by increasing cardiomyocyte contractility (ESC 2024) - "AC01 improved CO, SV, and EF in HF mice by increasing contractility in a load-independent fashion. AC01 increased cardiomyocyte contractility without affecting Ca2+ transient amplitudes, through ghrelin receptor Gαi signalling, leading to reduced phosphorylation of cTnI. AC01 improved left ventricle systolic function in monkeys."

Preclinical • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure • TNNI3

GOAL-HF1: Phase Ib/IIa Trial With AC01 in Patients With HFrEF (clinicaltrials.gov) - P1/2 | N=80 | Recruiting | Sponsor: AnaCardio AB | Trial completion date: Nov 2024 ➔ Jun 2025 | Trial primary completion date: Jun 2024 ➔ Jun 2025

Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure

GOAL-HF1: Phase Ib/IIa Trial With AC01 in Patients With HFrEF (clinicaltrials.gov) - P1/2 | N=80 | Recruiting | Sponsor: AnaCardio AB | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Congestive Heart Failure • Heart Failure

GOAL-HF1: Phase Ib/IIa Trial With AC01 in Patients With HFrEF (clinicaltrials.gov) - P1/2 | N=80 | Not yet recruiting | Sponsor: AnaCardio AB

New P1/2 trial • Cardiovascular • Congestive Heart Failure • Heart Failure